Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 39Tumor-Agnostic 10Breast 10Head & Neck 8Genitourinary 4Gastrointestinal 4Plasma cell 2Lymphoid 2CNS 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Glioma 1Glioblastoma 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Afatinib × CNS × Clear all
NCT00977431 2019-02-18

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

Boehringer Ingelheim

Phase 1 Completed
36 enrolled 16 charts
CNS

Glioblastoma

NCT00727506 2017-08-15

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Boehringer Ingelheim

Phase 2 Completed
151 enrolled 42 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡